LCL-161

DRACPC ID  DRACPC0038

Active Ingredients   LCL-161

Description  An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.

Synonyms  Smac Mimetic LCL161; LCL-161

Type  Small Molecule

Disease  Leukemia, Neoplasms, Solid Tumors, Breast Cancer, Ovarian Cancer

Classification

  

Inhibitor of IAP family of proteins Peptide and derivative

Structure Information


Molecular Formula  C26H33FN4O3S

Molecular Weight  500.6

Active Sequence  AX

Sequence Length  2

Modification  X=Chg-Unk, C-terminal Me

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide

InChI  InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1

InChI_Key UFPFGVNKHCLJJO-SSKFGXFMSA-N

SMILES  C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O

External Codes


PubChem CID  24737642

DrugBank Accession Number  DB12085

NCI Thesaurus Code  C91079  

UNII  6TNS415Y3P   GSRS

CAS  1005342-46-0



Drug approval


Drug indication
    LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01968915 A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors Neoplasms Phase 1 Treatment
NCT01955434 Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma Phase 2 Treatment
NCT02098161 Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis; Secondary Myelofibrosis Phase 2 Treatment
NCT01934634 Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer Phase 1 Treatment
NCT01240655 A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors Solid Tumors Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.